TrialNature medicine2026

Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.

Julio Rosenstock et al.PubMed ↗Publisher ↗

No numbers read from the abstract.